Abstract
Pancreatic ductal adenocarcinoma (PDAC) is the leading cause of cancer-related death worldwide. As PDAC is more common in older adults and the population is aging, the incidence of pancreatic adenocarcinoma is expected to increase in the coming years. As a result, the mechanism and clinical management of PDAC in the elderly population is receiving more attention. This review will discuss age-related morphological and pathological changes, clinical management, surgery and adjuvant therapies, and molecular changes in elderly PDAC patients. More research is needed to clarify molecular mechanisms and develop new prevention and treatment strategies for PDAC in elderly patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
